(R)-(+)-Thalidomide
CAS: 2614-06-4
Ref. 3D-FT28190
1mg | Descatalogado | ||
2mg | Descatalogado | ||
5mg | Descatalogado | ||
10mg | Descatalogado | ||
25mg | Descatalogado |
Información del producto
- (R)-(+)-2-(2,6-Dioxo-3-piperidinyl)-1H-iso-indole-1,3(2H)-dione(R)-ThalidomideNSC 91729
- (+)-Thalidomide
- 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (R)-
- 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-, (R)- (9CI)
- 1H-Isoindole-1,3(2H)-dione, 2-[(3R)-2,6-dioxo-3-piperidinyl]-
- 2-[(3R)-2,6-Dioxo-3-piperidinyl]-1H-isoindole-1,3(2H)-dione
- 2-[(3R)-2,6-Dioxopiperidin-3-yl]-2,3-dihydro-1H-isoindole-1,3-dione
- D-Thalidomide
- NSC 91729
- Phthalimide, N-(2,6-dioxo-3-piperidyl)-, (+)-
- Ver más sinónimos
- Phthalimide, N-(2,6-dioxo-3-piperidyl)-, <span class="text-smallcaps">D</span>-(+)-
- Phthalimide, N-(2,6-dioxo-3-piperidyl)-, D-(+)-
- R-(+)-Thalidomide
- R-(<span class="text-smallcaps">D</span>)-Thalidomide
- R-Lenalidomide
(R)-(+)-Thalidomide is a drug that is used for the treatment of cancer and other diseases. It is a racemic mixture of two enantiomers, (S)-(-)-thalidomide and (R)-(+)-thalidomide. The (+) enantiomer has been shown to be active in animal experiments and clinical trials as an anti-angiogenic agent. This drug binds to the alpha subunit of integrin molecules, which are proteins that mediate cell adhesion to the extracellular matrix. This binding inhibits the proliferation of tumor cells by blocking their interaction with the extracellular matrix and preventing new blood vessel formation. Thalidomide has been shown to inhibit angiogenesis in animal models, but not in humans.